SARS-CoV-2 Nucleoprotein (8-25) 0.5mg
NQRNAPRITFGGPSDSTG is a SARS-CoV-2 nucleoprotein (8-25) epitope. It is an epitope suitable for anti-viral targeting.
Catalogue number crb1001834h Molecular Weight 1873.9 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Gupta et al., (2006). SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology, 347(1): 127.
Zhuang et al., (2021). Mapping and role of T cell response in SARS-CoV-2–infected mice. JEM, 218(4). DOI: 10.1084/jem.20202187.
Manufactured in: United Kingdom
The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. The nucleoprotein has a critical role in virus assembly and RNA transcription. The nucleoprotein is essential in the formation of helical ribonucleoproteins and in regulating viral RNA synthesis. The nucleoprotein can also regulate infected host cellular mechanisms. It is highly expressed during infection and may induce protective immune responses against SARS-CoV and SARS-CoV-2.
The nucleoprotein residues NQRNAPRITFGGPSDSTG (8-25) from SARS-CoV-2 have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.